<p>Ruth Ruprecht of the Dana-Farber Cancer Institute in the U.S. will develop a new vaccine platform for HIV based on the hypothesis that immunodominant regions of the virus may be irrelevant to neutralizing the virus and also prevent access to neutralizing epitopes in conserved regions. The team will also use structural mimics of important epitopes in an effort to generate a strong, broadly neutralizing antibody response against these conversed sites.</p>


Ruth Ruprecht of the Dana-Farber Cancer Institute in the U.S. will develop a new vaccine platform for HIV based on the hypothesis that immunodominant regions of the virus may be irrelevant to neutralizing the virus and also prevent access to neutralizing epitopes in conserved regions. The team will also use structural mimics of important epitopes in an effort to generate a strong, broadly neutralizing antibody response against these conversed sites.

Novel HIV-1 Env Immunogens for Immuno-Focusing

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

.css-1nxq281{overflow:hidden;display:inline-block;}.css-1nxq281 span{display:inline-block;}Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

Great ideas come from everywhere.